Ascentage Pharma Builds Momentum With 2 'Potential Blockbuster' Drugs, Oppenheimer Says

MT Newswires Live03-27

Ascentage Pharma Group (AAPG) is entering 2026 with growing commercial momentum in China and a pipeline nearing major global readouts, including two "potential blockbuster" drugs, Oppenheimer said Friday in a report.

Olverembatinib, used for certain hard-to-treat leukemias, remained the company's top seller in 2025, with revenue rising 81% to $62.2 million from a year earlier, the report said. Lisaftoclax, a pill for blood cancers such as chronic lymphocytic leukemia, added $10.1 million in its first five months on the market, giving Ascentage a second meaningful product line, Oppenheimer said.

This year will be dominated by enrollment across nine global registration-focused studies, setting up multiple programs for possible regulatory filings in 2027, the report said.

Oppenheimer also pointed to early signs of strategic alignment around pairing lisaftoclax with APG-3288, another cancer drug Ascentage is developing, in chronic lymphocytic leukemia, a combination that may offer patients an all-oral, time-limited treatment option.

Oppenheimer maintained its outperform rating on Ascentage stock with a $45 price target.

Price: 23.12, Change: +1.82, Percent Change: +8.56

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment